Greenwich LifeSciences, Inc.

NasdaqCM GLSI

Greenwich LifeSciences, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -193,712.24%

Greenwich LifeSciences, Inc. EBT Margin is -193,712.24% for the Trailing 12 Months (TTM) ending September 30, 2024. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqCM: GLSI

Greenwich LifeSciences, Inc.

CEO	Mr. Snehal S. Patel
IPO Date	Sept. 25, 2020
Location	United States
Headquarters	Building 14
Employees	3
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Cosmetics Drugstores & Retail Pharmacies Pharmaceuticals Vaccines

Description

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Key trends

Past 5 years